Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea
· Delayed Price · Currency is KRW 2,600.00
+20.00 (0.78%)
At close: Mar 6, 2026
Prestige Biologics Revenue
Prestige Biologics had revenue of 8.90B KRW in the quarter ending December 31, 2025, with 194.53% growth. This brings the company's revenue in the last twelve months to 19.24B, up 397.28% year-over-year. In the fiscal year ending June 30, 2025, Prestige Biologics had annual revenue of 12.53B with 477.83% growth.
Revenue (ttm)
19.24B
Revenue Growth
+397.28%
P/S Ratio
10.51
Revenue / Employee
n/a
Employees
n/a
Market Cap
202.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.53B | 10.36B | 477.83% |
| Jun 30, 2024 | 2.17B | 423.21M | 24.24% |
| Jun 30, 2023 | 1.75B | 1.73B | 11,115.88% |
| Dec 31, 2022 | 15.57M | -3.21B | -99.52% |
| Dec 31, 2021 | 3.23B | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 66.39B |
| TiumBio | 9.32B |
| Ensol Biosciences | 537.46M |
| Kangstem Biotech | 12.77B |
| QuadMedicine | 13.11B |
| Genome & Company | 25.95B |
| ABION | 1.03B |
| Bio Solution | 8.27B |